ASD 253
Alternative Names: ASD-253Latest Information Update: 29 Apr 2024
At a glance
- Originator Ascendo Biotechnology
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 29 Apr 2024 ASD 253 is available for licensing as of 29 Apr 2024. www.ascendobiotech.com/partnering
- 11 Apr 2024 Preclinical trials in Hepatitis B in Taiwan (unspecified route) (Ascendo Biotechnology pipeline; April 2024)
- 11 Apr 2024 Ascendo Biotechnology plans phase-I trial for Hepatitis-B (Ascendo Biotechnology website, April 2024) (https://www.ascendobiotech.com/about/)